Evidence map›Paper›PMID 31720017›Full record

ArticleActa naturae

The Structural and Immunological Properties of Chimeric Proteins Containing HIV-1 MPER Sites.

A P Rudometov, N B Rudometova, D N Shcherbakov, A A Lomzov, O N Kaplina, N S Shcherbakova, A A Ilyichev, A Yu Bakulina, L I Karpenko

Open access · diamondAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Acta naturae. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
0.1field-weighted citation impact, top 52% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 1 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 4 institutions in 1 country.

A P RudometovState Research Center of Virology and Biotechnology "Vector", Koltsovo, Novosibirsk region, 630559 , Russia.
N B RudometovaState Research Center of Virology and Biotechnology "Vector", Koltsovo, Novosibirsk region, 630559 , Russia.
D N ShcherbakovState Research Center of Virology and Biotechnology "Vector", Koltsovo, Novosibirsk region, 630559 , Russia.
A A LomzovInstitute of Chemical Biology and Fundamental Medicine SB RAS, Ac. Lavrentieva Ave. 8, Novosibirsk, 630090, Russia.
O N KaplinaState Research Center of Virology and Biotechnology "Vector", Koltsovo, Novosibirsk region, 630559 , Russia.
N S ShcherbakovaState Research Center of Virology and Biotechnology "Vector", Koltsovo, Novosibirsk region, 630559 , Russia.
A A IlyichevState Research Center of Virology and Biotechnology "Vector", Koltsovo, Novosibirsk region, 630559 , Russia.
A Yu BakulinaState Research Center of Virology and Biotechnology "Vector", Koltsovo, Novosibirsk region, 630559 , Russia.
L I KarpenkoState Research Center of Virology and Biotechnology "Vector", Koltsovo, Novosibirsk region, 630559 , Russia.
State Research Center of Virology and Biotechnology VECTOR · RUAltai State University · RUNovosibirsk State University · RUSiberian Branch of the Russian Academy of Sciences · RU

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The human immunodeficiency virus (HIV-1) poses a serious risk to global public health. The development of a safe and effective vaccine could stop the HIV/AIDS pandemic. Much of the research focused on HIV-1 prevention through vaccination is aimed at developing immunogens and immunization strategies to induce the formation of antibodies with neutralizing activity against a broad range of HIV-1 isolates (bNAbs). The objective of this study was to develop immunogens capable of targeting an immune response to MPER, one of the regions of bNAb binding in Env. Two immunogens carrying MPER fragments on their scaffolds (protein YkuJ Bacillus subtilis and artificial polypeptide TBI) were constructed. Circular dichroism spectroscopy was used to show that the secondary structure of the immunogens was consistent with their theoretical models. The antigenic structure of the MPER-TBI and YkuJ-MPER proteins was characterized using bNAbs that recognize HIV-1 MPER (2F5, 4E10, and 10E8). The rabbit model made it possible to show the immunogenicity of the constructed recombinant proteins. The resulting serum was found to be cross-reactive with immunogens carrying MPER. The constructs designed and characterized in this study can be used for targeting the humoral immune response to MPER, which is known to be one of the sites of HIV-1 vulnerability.

Indexed as

bNAbsHIV-1MPERneutralizing antibody epitopesrecombinant immunogens

Identifiers

PMID31720017
PMCPMC6826149
OpenAlexW2981761505

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.